Story thread · 2 reports / 2 sources
BioMarin to gain hypophosphatasia drug under Alesta buyout
seekingalpha.com · 19h · first report
The coverage
- BioMarin to acquire Alesta Therapeutics for up to $490 million
investing.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.